Genmab AS Financials
| GNMSF Stock | USD 212.50 4.81 2.32% |
Genmab |
Understanding current and past Genmab AS Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genmab AS's financial statements are interrelated, with each one affecting the others. For example, an increase in Genmab AS's assets may result in an increase in income on the income statement.
Genmab AS Stock Summary
Genmab AS competes with Inhibikase Therapeutics, Purple Biotech, Synaptogenix, Legend Biotech, and Blueprint Medicines. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Kalvebod Brygge 43, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.genmab.com |
| Phone | 45 70 20 27 28 |
| Currency | USD - US Dollar |
Genmab AS Key Financial Ratios
There are many critical financial ratios that Genmab AS's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Genmab AS reports annually and quarterly.| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Target Price | 383.57 | |||
| Beta | 0.67 | |||
| Z Score | 25.2 |
Genmab Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genmab AS's current stock value. Our valuation model uses many indicators to compare Genmab AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genmab AS competition to find correlations between indicators driving Genmab AS's intrinsic value. More Info.Genmab AS is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genmab AS is roughly 2.29 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genmab AS's earnings, one of the primary drivers of an investment's value.Genmab AS Systematic Risk
Genmab AS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genmab AS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Genmab AS correlated with the market. If Beta is less than 0 Genmab AS generally moves in the opposite direction as compared to the market. If Genmab AS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genmab AS is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genmab AS is generally in the same direction as the market. If Beta > 1 Genmab AS moves generally in the same direction as, but more than the movement of the benchmark.
Genmab AS November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Genmab AS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genmab AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genmab AS based on widely used predictive technical indicators. In general, we focus on analyzing Genmab Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genmab AS's daily price indicators and compare them against related drivers.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 13.03 | |||
| Value At Risk | (4.83) | |||
| Potential Upside | 3.34 |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |